TIPS-Protected Nucleoside Monomers for 3′-RNA Oligonucleotide Synthesis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The chemical synthesis of oligonucleotides comprising at least one nucleoside with a 3′-hydroxyl group is challenging due to the instability of commonly used protecting groups under deprotection conditions, leading to low yields and high impurities.

Innovation Solution

The use of nucleoside phosphoramidite monomers with a triisopropylsilylether (TIPS) protected 3′-hydroxyl group for coupling and subsequent oxidation or sulfurization to form phosphate triester or phosphorothioate intermediates, followed by deprotection to obtain oligonucleotides with improved yields and reduced impurities.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If commonly used protecting groups are used in oligonucleotide synthesis, then the synthesis process is routine and straightforward, but the protecting groups become unstable under deprotection conditions leading to low yields and high impurities

Engineering Contradiction:
Improveease of synthesisVSAvoidstability of protecting groups
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The patent changes the chemical parameter of the protecting group from commonly used groups (like TBS, TMS) to a specific triisopropylsilylether (TIPS) protecting group. This parameter change enables the group to withstand the harsh deprotection conditions (strong base, heat) while maintaining stability during synthesis, thereby resolving the contradiction between ease of synthesis and stability under deprotection conditions.

Inventive Principle:
Principle #35Parameter changes

2Productivity

If commonly used protecting groups are used, then the synthesis procedure is simple, but the yield of modified oligonucleotides is low due to instability

Engineering Contradiction:
Improveyield of oligonucleotideVSAvoidstability under deprotection
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent applies parameter change by selecting a specific protecting group (TIPS) with enhanced chemical stability. This allows the protecting group to survive the deprotection process without decomposing, thereby preventing yield loss and improving the overall productivity of oligonucleotide synthesis.

Inventive Principle:
Principle #35Parameter changes

3Manufacturing precision

If commonly used protecting groups are used, then the synthesis is routine, but impurities increase due to deprotection instability

Engineering Contradiction:
Improvepurity of oligonucleotideVSAvoidprotecting group stability
Core Design Contradiction:
Manufacturing precisionVSReliability

Solution Approach 1:

The patent changes the chemical parameter of the protecting group to TIPS, which is specifically designed to be stable under deprotection conditions. This prevents unwanted side reactions and decomposition during the process, thereby reducing impurities and improving manufacturing precision.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method enables the synthesis of oligonucleotides with enhanced yields and purity, particularly for sequences ranging from about 6 to 50 nucleotides, using automated synthesizers and suitable solvents for coupling, oxidation, and deprotection steps.

Implementation Method 1

The coupling forms a phosphite triester intermediate which can be oxidized or sulfurized to form a phosphate triester or phosphorothioate intermediate

Methodology Applied
Scientific EffectOxidation: Oxidation

Implementation Method 2

The coupling forms a phosphite triester intermediate which can be oxidized or sulfurized to form a phosphate triester or phosphorothioate intermediate

Methodology Applied
Scientific EffectSulfurization:

Data Source

PatentUS20250325575A2Synthesis of 3 -RNA oligonucleotides
Publication Date: 2025.10.23 ALNYLAM PHARMACEUTICALS INC
  • US20250325575A2 patent drawing
  • US20250325575A2 patent drawing
  • US20250325575A2 patent drawing

AI summary

The disclosure is directed to monomers and methods for synthesizing oligonucleotides comprising at least one nucleoside comprising a 3′-hydroxyl group.